Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

NCT03679754 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: Ad-RTS-hIL-12
DRUG: veledimex

Sponsor

Alaunos Therapeutics